Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children

Bone Marrow Transplantation
D T SchneiderW Nürnberger

Abstract

The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 +/- 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMT-related complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores > or =10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P < 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores > or =10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 +/- 0.15 vs 0.27 +/- 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following...Continue Reading

References

Jan 1, 1988·Intensive Care Medicine·C TorrecillaE Dominguez de Villota
Nov 1, 1988·Critical Care Medicine·M M PollackP R Getson
Sep 1, 1994·Critical Care Medicine·D G NicholsM C Rogers
Mar 1, 1996·Intensive Care Medicine·A van VeenE van der Voort
May 1, 1997·Annals of Hematology·W NürnbergerU Göbel
Sep 10, 1998·American Journal of Respiratory and Critical Care Medicine·K J PriceB S Andersson
Nov 25, 1998·Bone Marrow Transplantation·A B WarwickJ P Neglia
Jan 14, 1999·Intensive Care Medicine·J P MarcinU E Ruttimann

❮ Previous
Next ❯

Citations

Dec 31, 2003·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Robert F TamburroHong-Bin Fang
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Jacques LacroixUNKNOWN Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Robert Tamburro
Jul 1, 2009·Journal of Pediatric Hematology/oncology·Oguz DursunAkif Yesilipek
May 25, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Surender RajasekaranRobert F Tamburro
Feb 3, 2009·Clinics in Chest Medicine·John R McArdle
Nov 25, 2005·Pediatric Transplantation·Kevin J SullivanMichael Joyce
Jan 4, 2017·Journal of Korean Medical Science·Ok Jeong LeeJoongbum Cho
Nov 15, 2005·Bone Marrow Transplantation·M A BarronS Zlotkin
Mar 13, 2019·Journal of Global Oncology·Gull Zareen Khan Sial, Saadiya Javed Khan
Mar 19, 2020·Pediatric Blood & Cancer·Pravin RrJudith Ju-Ming Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.